Fluosol

From Wikipedia, the free encyclopedia

Fluosol is an artificial blood substitute which is milky in color. Its main ingredients are perfluorodecalin or perfluorotributylamine in Fluosol-DA and Fluosol-43 respectively, perfluorochemicals suspended in an albumin emulsion. It was developed in Japan and first tested in the United States in 1982, its recipients being individuals who refused blood transfusions on religious grounds. Fluosol serves as a dissolving medium for oxygen. In order to "load" sufficient amounts of oxygen into it, patients must breathe pure oxygen by mask or must be in a hyperbaric chamber. While initially promising for therapy of heart attack, carbon monoxide poisoning, and sickle-cell anemia, research also indicates that Fluosol may depress the patient's immune system.^[1]

Fluosol is the only blood substitute approved to date by the FDA for medical use in the circulatory system (NDA N860909, 1989). The U.S.FDA and eight other countries approved Fluosol indicated to “reduce the amount of allogeneic blood units transfused.” From 1989 to 1992, Fluosol was used in more than 40,000 human subjects. Due to difficulty with the emulsion storage of Fluosol use (frozen storage and rewarming), its popularity declined and its production ended.

[edit] References